898 related articles for article (PubMed ID: 18278853)
21. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier.
Pardridge WM; Boado RJ
Methods Enzymol; 2012; 503():269-92. PubMed ID: 22230573
[TBL] [Abstract][Full Text] [Related]
22. Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins.
Ma Q; DeMarte L; Wang Y; Stanners CP; Junghans RP
Cancer Gene Ther; 2004 Apr; 11(4):297-306. PubMed ID: 15002034
[TBL] [Abstract][Full Text] [Related]
23. [Construction and expression of anti-tumor necrosis factor related apoptosis-inducing ligand receptor death receptor 5 chimeric antibody in eukaryotic cells].
Chen F; Guo YB; Liu SL; Zheng DX; Liu YX
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Dec; 30(6):690-5. PubMed ID: 19180918
[TBL] [Abstract][Full Text] [Related]
24. Expression of chimeric antibody in mammalian cells using dicistronic expression vector.
Xiong KH; Liang QC; Xiong H; Zou CX; Gao GD; Zhao ZW; Zhang H
Biotechnol Lett; 2005 Nov; 27(21):1713-7. PubMed ID: 16247680
[TBL] [Abstract][Full Text] [Related]
25. High-level expression of proteins in mammalian cells using transcription regulatory sequences from the Chinese hamster EF-1alpha gene.
Running Deer J; Allison DS
Biotechnol Prog; 2004; 20(3):880-9. PubMed ID: 15176895
[TBL] [Abstract][Full Text] [Related]
26. IgG-single chain Fv fusion protein therapeutic for Alzheimer's disease: Expression in CHO cells and pharmacokinetics and brain delivery in the rhesus monkey.
Boado RJ; Lu JZ; Hui EK; Pardridge WM
Biotechnol Bioeng; 2010 Feb; 105(3):627-35. PubMed ID: 19816967
[TBL] [Abstract][Full Text] [Related]
27. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII.
Davies J; Jiang L; Pan LZ; LaBarre MJ; Anderson D; Reff M
Biotechnol Bioeng; 2001 Aug; 74(4):288-94. PubMed ID: 11410853
[TBL] [Abstract][Full Text] [Related]
28. [Construction of anti-human VEGF165 chimeric antibodies and expression in eukaryotic cells].
Ran Y; Yang Z; Wang G
Zhonghua Zhong Liu Za Zhi; 1999 Nov; 21(6):412-5. PubMed ID: 11776613
[TBL] [Abstract][Full Text] [Related]
29. Construction and characterization of the chimeric antibody 8C11 to the hepatitis E virus.
Luo W; Chen Y; Li L; Xu C; Miao J; Shih JW; Zhang J; Xia N
FEMS Immunol Med Microbiol; 2007 Oct; 51(1):18-25. PubMed ID: 17645530
[TBL] [Abstract][Full Text] [Related]
30. Imaging amyloid plaque in Alzheimer's disease brain with a biotinylated Aβ peptide radiopharmaceutical conjugated to an IgG-avidin fusion protein.
Sumbria RK; Boado RJ; Pardridge WM
Bioconjug Chem; 2012 Jun; 23(6):1318-21. PubMed ID: 22624578
[TBL] [Abstract][Full Text] [Related]
31. Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse.
Zhou QH; Boado RJ; Lu JZ; Hui EK; Pardridge WM
Mol Pharm; 2010 Dec; 7(6):2148-55. PubMed ID: 20860349
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase a and a monoclonal antibody against the human insulin receptor.
Boado RJ; Lu JZ; Hui EK; Sumbria RK; Pardridge WM
Biotechnol Bioeng; 2013 May; 110(5):1456-65. PubMed ID: 23192358
[TBL] [Abstract][Full Text] [Related]
33. [The high level expression of CTLA-4/Ig fusion protein in CHO cell].
Zheng LH; Liu QS
Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Jun; 38(3):370-3. PubMed ID: 17593809
[TBL] [Abstract][Full Text] [Related]
34. Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein.
Boado RJ; Hui EK; Lu JZ; Zhou QH; Pardridge WM
J Biotechnol; 2010 Mar; 146(1-2):84-91. PubMed ID: 20100527
[TBL] [Abstract][Full Text] [Related]
35. Genetically engineered clostridial C2 toxin as a novel delivery system for living mammalian cells.
Fahrer J; Plunien R; Binder U; Langer T; Seliger H; Barth H
Bioconjug Chem; 2010 Jan; 21(1):130-9. PubMed ID: 20030334
[TBL] [Abstract][Full Text] [Related]
36. Delivery of a peptide radiopharmaceutical to brain with an IgG-avidin fusion protein.
Zhou QH; Lu JZ; Hui EK; Boado RJ; Pardridge WM
Bioconjug Chem; 2011 Aug; 22(8):1611-8. PubMed ID: 21707084
[TBL] [Abstract][Full Text] [Related]
37. Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse.
Boado RJ; Zhang Y; Wang Y; Pardridge WM
Biotechnol Bioeng; 2009 Mar; 102(4):1251-8. PubMed ID: 18942151
[TBL] [Abstract][Full Text] [Related]
38. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor.
Coloma MJ; Lee HJ; Kurihara A; Landaw EM; Boado RJ; Morrison SL; Pardridge WM
Pharm Res; 2000 Mar; 17(3):266-74. PubMed ID: 10801214
[TBL] [Abstract][Full Text] [Related]
39. Selective plasma pharmacokinetics and brain uptake in the mouse of enzyme fusion proteins derived from species-specific receptor-targeted antibodies.
Zhou QH; Boado RJ; Pardridge WM
J Drug Target; 2012 Sep; 20(8):715-9. PubMed ID: 22845843
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate of avidin and a monoclonal antibody to the transferrin receptor.
Kang YS; Bickel U; Pardridge WM
Drug Metab Dispos; 1994; 22(1):99-105. PubMed ID: 8149897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
